The preliminary therapeutic proof, together with the potential pharmacological benefits of 5?MeO?copyright versus other classical psychedelics, has established intriguing to researchers and pharmaceutical companies alike, fueling a developing range of medical trials which are now in numerous phases of progress (Desk one). At present, two clinical